Cannabidiol

• Randomized, double-blind, Placebo-controlled, 2x2 cross over study assessing the efficacy and safety of cANnabidiol oral solution for joint … Not authorised
  2023-505380-36-00 Phase III 1 country Institut Gustave Roussy
• Randomized, double-blind, Placebo-controlled, 2x2 cross over study assessing the efficacy and safety of cANnabidiol oral solution for joint … Pending
  2023-505380-36-01 Phase III 1 country Institut Gustave Roussy
• IMpAct of CardiolRxTM oVer 6 months following IL-1 Blocker cessation in pERICarditis patients – MAVERIC: A randomized, double-blind, placebo… Pending
  2024-517688-21-00 Phase III 2 countries Cardiol Therapeutics Inc.
• Effect of Cannabidiol on Muscle Mass and Mitochondrial Function in Head and Neck Cancer Pending
  2024-519637-32-00 Phase II 1 country University Hospital Of Clermont-Ferrand
• Effectiveness of CBD on behavioural problems in patients with TSC, FXS and Sanfilippo Pending
  2025-520846-31-00 Phase III 1 country Amsterdam UMC Stichting
• CBD-SIB - Efficacy of cannabidiol in the management of Self-Injurious Behavior in children and adolescents with severe neurodevelopmental di… Pending
  2025-521161-27-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• AugmENtation witH cAnnabidiol iN first episode psyChosis: a doublE blind randomised controlled trial (STEP-ENHANCE Trial) Pending
  2025-521929-32-01 Phase III 6 countries University Of Oxford
• Efficacy and safety of cannabidiol to patients with advanced prostate cancer Recruiting
  2024-513951-33-00 Phase II 1 country Regionshospital Nordjylland
• The effect of CBD on sleep quality following late evening exercise Recruiting
  2024-518609-17-00 Phase II 1 country UZ Leuven
• A trial to investigate the effects of Cannabidiol plus Naltrexone on alcohol craving in patients with alcohol dependence Recruiting
  2024-518164-12-00 Phase II 1 country Zentralinstitut Fuer Seelische Gesundheit
• A Pilot / Phase 2 Clinical Trial of GSL-01-001 Administered Orally for 12 Weeks Preceded by a 2 Week Screening Period in Patients Presenting… Recruiting
  2024-514685-39-00 Phase II 1 country Cannabibs Sp. z o.o.
• Small patient study to explore the anticancer effect of cannabis oil in untreatable patients with liver cancer Recruiting
  2024-514049-13-02 Phase II 1 country Universitair Medisch Centrum Groningen
• CBD-OH - Cannabidiol as an add-on treatment during inpatient alcohol cessation in patients with severe alcohol use disorder: a Phase II tria… Recruiting
  2024-518455-28-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• BOOSTCAMP: Boosting the endocannabinoid system before the treatment of anxiety symptoms Ended
  2024-514783-78-00 Phase II 1 country Universitair Medisch Centrum Utrecht
• Clinical study to assess the efficacy and safety of Cannabidiol in children and young adults with rare disease-associated severe epilepsy Ended
  2023-503709-12-00 Phase II 1 country Azienda Ospedaliero Universitaria Meyer IRCCS
• Enhancing recovery in early schizophrenia: A study comparing cannabidiol and placebo as add-on to standard antipsychotic treatment. Halted
  2024-517198-26-00 Phase II 1 country Zentralinstitut Fuer Seelische Gesundheit
• Cannabidiol for reducing drinking in alcohol use disorder and modifying the effects of alcohol on the brain and the liver Ended
  2024-517751-13-01 Phase II 1 country Centre Hospitalier Le Vinatier
• A study to investigate behavioral and other co-occurring outcomes with Epid(i/y)olex as add-on therapy in participants aged 1 to 65 years of… Ended
  2023-507426-17-00 Phase III/IV 1 country Jazz Pharmaceuticals Research UK Limited
• Cannabidiol for treatment of non-affective psychosis and cannabis use Ended
  2024-517630-18-00 Phase II/III 1 country Region Hovedstaden
• An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003‑P) in… Ended
  2023-505851-33-00 Phase III 2 countries Gw Research Limited; Jazz Pharmaceuticals Research UK Limited
• A study where all patients receive the test drug, in order to understand the consequences of long-term test drug use on the human body. All … Ended
  2023-508165-33-00 Phase III 1 country Harmony Biosciences Management Inc.
• The CanISleepinMS Study Ended
  2024-518280-35-00 Phase II 1 country Wageningen Research Stichting
• Study to assess the effects of oral cannabidiol in healthy male subjects on CNS using the NeuroCart test battery and TMS. Ended
  2023-508311-23-00 Phase II 1 country Centre for Human Drug Research
• Effects and Safety of Test drug ZYN002, applied as a gel onto the skin of children, adolescents and young adults with a certain hereditary d… Ended
  2024-513888-99-00 Phase III 1 country Harmony Biosciences Management Inc.

Showing 1–24 of 26 trials